BillionToOne Inc/$BLLN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About BillionToOne Inc
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
- Ticker
- $BLLN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 713
- Headquarters
- Menlo Park, United States
- Website
- www.billiontoone.com
BillionToOne Inc Metrics
BasicAdvanced
$5.4B
148.10
$0.77
-
-
Price and volume
Market cap
$5.4B
52-week high
$150.44
52-week low
$61.96
Average daily volume
526K
Financial strength
Current ratio
11.689
Quick ratio
11.189
Long term debt to equity
0.256
Total debt to equity
0.268
Interest coverage (TTM)
1,056.15%
Profitability
EBITDA (TTM)
50.239
Gross margin (TTM)
71.27%
Net profit margin (TTM)
8.35%
Operating margin (TTM)
10.90%
Effective tax rate (TTM)
0.51%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
5.19%
Return on equity (TTM)
10.68%
Valuation
Price to earnings (TTM)
148.098
Price to revenue (TTM)
9.682
Price to book
9.93
Price to tangible book (TTM)
9.93
Price to free cash flow (TTM)
116.132
Free cash flow yield (TTM)
0.86%
Free cash flow per share (TTM)
0.981
Growth
Revenue change (TTM)
90.12%
Earnings per share change (TTM)
-125.73%
What the Analysts think about BillionToOne Inc
Analyst ratings (Buy, Hold, Sell) for BillionToOne Inc stock.
Analyst projections of the future price of BillionToOne Inc stock.
Bulls say / Bears say
Second-quarter revenue rose 64% year on year, while gross margin reached 70% and operating income turned positive at $5.5 million. That is strong growth with improving profitability, not just expansion at any cost. (BillionToOne)
A peer-reviewed head-to-head study found Northstar Response agreed with a tumour-informed test on the direction of tumour-burden changes in 94% of evaluable pairs. The tissue-free approach could help differentiate BillionToOne’s oncology offering, though broader clinical use still needs to be demonstrated. (BillionToOne)
A prospective study across nine US institutions assessed Unity fetal-risk screening in 2,212 pregnancies, adding evidence for use in routine prenatal care. The expanded 130-gene panel also broadens the company’s prenatal test offering. (BillionToOne, BillionToOne)
Prenatal tests generated 88% of first-half revenue, while oncology contributed 11%, leaving the business reliant on one dominant product area. A slowdown in prenatal growth could therefore outweigh progress in the smaller oncology segment. (SEC)
Operating expenses rose 59% year on year to $71.6 million, leaving a 5% operating margin despite fast sales growth. Oncology tests cost more per test, so a faster shift towards oncology could put pressure on margins. (BillionToOne)
Revenue relies mainly on third-party payers, and management said more than $10 million of claims were being held while payer codes were implemented. The Northstar Response comparison study was also small, covering 61 patients, and the test is not FDA-cleared or approved, which may make wider adoption and reimbursement harder to secure. (SEC, BillionToOne)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
BillionToOne Inc Financial Performance
Revenues and expenses
BillionToOne Inc Earnings Performance
Company profitability
Upcoming events
No upcoming events
BillionToOne Inc News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.